Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2020
Adaptimmune reports first-quarter 2020 financial results
Adaptimmune reported financial results for the first quarter ended March 31, 2020, including revenue of $0.8 million and a net loss of $28.2 million attributable to holders of its ordinary shares.
2020
Astellas and Adaptimmune agree to develop T-cell therapies
Astellas Pharma and Adaptimmune said they would select three molecular targets and develop T-cell-based therapies against them, including CAR-T and T-cell receptor therapies. Astellas agreed to pay $50 million upfront and up to $897 million in milestone payments.